Diego Roza, CarmenCruz Carmona, M JesúsFernández Álvarez, RamónFerrer Sancho, JaumeMarín Martínez, BelénMartínez González, CristinaRodríguez Portal, José AntonioRomero Valero, FernandoVillena Garrido, María Victoria2025-07-312025-07-312017-08-01Roza CD, Cruz Carmona MJ, Álvarez RF, Sancho JF, Martínez BM, González CM, et al. Recomendaciones sobre el diagnóstico y manejo de la enfermedad pleural y pulmonar por asbesto. Arch Bronconeumol. 2017;53:437–442.1579-212910.1016/j.arbr.2017.05.017https://hdl.handle.net/20.500.14352/122944Asbestos is the term used for a set of mineral silicates that tend to break up into fibers. Its use has been associated with numerous diseases affecting the lung and pleura in particular, all of which are characterized by their long period of latency. Asbestos, moreover, has been recognized by the WHO as a Group IA carcinogen since 1987 and its use was banned in Spain in 2002. The publication in 2013 of the 3rd edition of the specific asbestos health monitoring protocol, together with the development of new diagnostic techniques, prompted the SEPAR EROM group to sponsor publication of guidelines, which review the clinical, radiological and functional aspects of the different asbestos-related diseases. Recommendations have also been made for the diagnosis and follow-up of exposed patients. These recommendations were drawn up in accordance with the GRADE classification system.engreview articlehttps://doi.org/10.1016/j.arbr.2017.05.017https://www.sciencedirect.com/science/article/pii/S1579212917301945restricted access616.24AsbestosCancerMesotheliomaPleuraNeumología3205.08 Enfermedades Pulmonares